EUCTR2010-024014-60-DE进行中（未招募）1 期
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinoma - A Study in Non-Small Cell Lung Cancer
Eli Lilly and Company Limited, Indianapolis0 个研究点目标入组 156 人开始时间: 2010年12月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be at least 18 years of age with histologically or cytologically confirmed Stage IV (AJCC edition 7) nonsquamous non-small cell lung carcinoma. Patients may have either measurable or nonmeasurable disease based on the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v. 1.1), and must have Eastern Cooperative Oncology Group status of 0 or 1as well as adequate hematologic, coagulation, and organ function. Patients must have fasting serum glucose <125mg/dL (6.9 mmol/L), and hemoglobin A1C =6%.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 62
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 94
排除标准
- •Patients must not have an uncontrolled intercurrent illness, leptomeningeal disease, or active infection requiring parenteral therapy.
研究者
相似试验
进行中（未招募）
1 期
A Study in Non-Small Cell Lung Canceradvanced nonsquamous non-small cell lung carcinomaMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024014-60-BEEli Lilly and Company Limited, Indianapolis156
已完成
2 期
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinoma10027656Lung cancerNL-OMON38158Eli Lilly10
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesEUCTR2020-004175-41-ITeoImmuneTech, Inc.127
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesAdvanced or metastatic gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC) progressed on or intolerant to 2 or more prior lines of systemic therapyMedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082464Term: Advanced gastric carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.1Level: LLTClassification code 10084873Term: Gastrooesophageal junction cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10079913Term: Adenocarcinoma of the gastroesophageal junction stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030145Term: Oesophageal adenocarcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004175-41-ESeoImmuneTech, Inc.127
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of the combination of durvalumab with azacitidine to treat a cancer of the bone marrow, causing cancer cell proliferation and improper normal blood cell production.Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2015-003596-30-PLCelgene International II Sàrl182